Dernière mise à jour : 02 septembre 2016
Détails
FichiersGeneric Name:
Panitumumab
État du projet:
Terminé
Domaine thérapeutique:
Metastatic Colorectal Cancer
Fabricant:
Amgen Canada Inc.
Brand Name:
Vectibix
Gamme de produits:
Examen en vue du remboursement
Numéro de projet :
PC0060-000
Strength:
20mg/mL (100mg vial)
Tumour Type:
Gastrointestinal
Indications:
Metastatic Colorectal Cancer
Funding Request:
For the treatment of patients with WT RAS mCRC in first line treatment setting in combination with FOLFOX
Review Status:
Complete
Pre Noc Submission:
Yes
Date NOC Issued:
Sponsor:
Amgen Canada Inc.
Submission Date:
Submission Deemed Complete:
Priorisation demandée:
Non demandée
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommandation:
Remboursement sous critères cliniques ou conditions
pERC Meeting:
Final Recommendation Issued:
Fichiers
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
Dernière mise à jour : 02 septembre 2016